1851-P: Bromocriptine (B) plus Curcumin (C) Interact to Reduce Advanced Fibrosis in a Mouse Methionine-Choline Deficient (MCD) Diet Model of Nonalcoholic Steatohepatitis (NASH)

NASH is characterized by severe hepatic fibrosis that potentiates cirrhosis and hepatocellular carcinoma. The MCD diet also potentiates severe liver fibrosis by reducing lipid secretion and antioxidant defenses, and adversely altering the gut microbiome to promote liver inflammation and damage. B, a...

Full description

Saved in:
Bibliographic Details
Published inDiabetes (New York, N.Y.) Vol. 68; no. Supplement_1
Main Authors TSAI, TSUNG-HUANG, CINCOTTA, ANTHONY
Format Journal Article
LanguageEnglish
Published New York American Diabetes Association 01.06.2019
Subjects
Online AccessGet full text

Cover

Loading…
Abstract NASH is characterized by severe hepatic fibrosis that potentiates cirrhosis and hepatocellular carcinoma. The MCD diet also potentiates severe liver fibrosis by reducing lipid secretion and antioxidant defenses, and adversely altering the gut microbiome to promote liver inflammation and damage. B, a dopamine D2 receptor agonist reduces adipose lipolysis and hepatic lipogenesis and inflammation. C improves a gut microbiome adverse to liver. C is also known to augment brain dopaminergic activity. We therefore investigated if B and C combination therapy that engages different pathological targets of NASH may provide an additive/synergistic benefit against MCD diet induced liver fibrosis. C57B6 mice were fed an MCD diet for 8 weeks to induce NASH with fibrosis then randomized to 4 treatment groups: Vehicle, B (10mg/kg), C (100mg/kg), and combination of B and C (BC) daily for 4 weeks while maintained on the diet. A group of mice on normal diet were used as normal reference control. BC therapy led to significant reductions of serum ALT (85%), serum AST (33.4%), liver steatosis (65.4%), inflammation (86.7%), ballooning degeneration (60%), and NAFLD activity score (86.4%), as well as gene expression markers each of fibrosis (αSMA, TGFβ, COL1A, TXNIP) by 88-92%, inflammation (TNFa, IL1β, MCP1, iNOS) by 91-97%, ER stress (DDIT3, ATF, sXBP1, HSPA5) by 45-93%, steatosis (ACC1, PLIN2) by 31-97%, and fatty acid oxidation (PPARα, PGC1α, CPT1, UCP1) by 65-86, and reduced the percent fibrosis area by 92.7% relative to vehicle (and resultantly similar to normal diet mice) (all above: P<0.05) and by amounts greater than B or C alone or additively. This study demonstrates the positive interactive effects of bromocriptine and curcumin on advanced liver fibrosis in an MCD diet model of NASH. Disclosure T. Tsai: Employee; Self; VeroScience LLC. A. Cincotta: Employee; Self; VeroScience LLC.
AbstractList NASH is characterized by severe hepatic fibrosis that potentiates cirrhosis and hepatocellular carcinoma. The MCD diet also potentiates severe liver fibrosis by reducing lipid secretion and antioxidant defenses, and adversely altering the gut microbiome to promote liver inflammation and damage. B, a dopamine D2 receptor agonist reduces adipose lipolysis and hepatic lipogenesis and inflammation. C improves a gut microbiome adverse to liver. C is also known to augment brain dopaminergic activity. We therefore investigated if B and C combination therapy that engages different pathological targets of NASH may provide an additive/synergistic benefit against MCD diet induced liver fibrosis. C57B6 mice were fed an MCD diet for 8 weeks to induce NASH with fibrosis then randomized to 4 treatment groups: Vehicle, B (10mg/kg), C (100mg/kg), and combination of B and C (BC) daily for 4 weeks while maintained on the diet. A group of mice on normal diet were used as normal reference control. BC therapy led to significant reductions of serum ALT (85%), serum AST (33.4%), liver steatosis (65.4%), inflammation (86.7%), ballooning degeneration (60%), and NAFLD activity score (86.4%), as well as gene expression markers each of fibrosis (αSMA, TGFβ, COL1A, TXNIP) by 88-92%, inflammation (TNFa, IL1β, MCP1, iNOS) by 91-97%, ER stress (DDIT3, ATF, sXBP1, HSPA5) by 45-93%, steatosis (ACC1, PLIN2) by 31-97%, and fatty acid oxidation (PPARα, PGC1α, CPT1, UCP1) by 65-86, and reduced the percent fibrosis area by 92.7% relative to vehicle (and resultantly similar to normal diet mice) (all above: P<0.05) and by amounts greater than B or C alone or additively. This study demonstrates the positive interactive effects of bromocriptine and curcumin on advanced liver fibrosis in an MCD diet model of NASH.
NASH is characterized by severe hepatic fibrosis that potentiates cirrhosis and hepatocellular carcinoma. The MCD diet also potentiates severe liver fibrosis by reducing lipid secretion and antioxidant defenses, and adversely altering the gut microbiome to promote liver inflammation and damage. B, a dopamine D2 receptor agonist reduces adipose lipolysis and hepatic lipogenesis and inflammation. C improves a gut microbiome adverse to liver. C is also known to augment brain dopaminergic activity. We therefore investigated if B and C combination therapy that engages different pathological targets of NASH may provide an additive/synergistic benefit against MCD diet induced liver fibrosis. C57B6 mice were fed an MCD diet for 8 weeks to induce NASH with fibrosis then randomized to 4 treatment groups: Vehicle, B (10mg/kg), C (100mg/kg), and combination of B and C (BC) daily for 4 weeks while maintained on the diet. A group of mice on normal diet were used as normal reference control. BC therapy led to significant reductions of serum ALT (85%), serum AST (33.4%), liver steatosis (65.4%), inflammation (86.7%), ballooning degeneration (60%), and NAFLD activity score (86.4%), as well as gene expression markers each of fibrosis (αSMA, TGFβ, COL1A, TXNIP) by 88-92%, inflammation (TNFa, IL1β, MCP1, iNOS) by 91-97%, ER stress (DDIT3, ATF, sXBP1, HSPA5) by 45-93%, steatosis (ACC1, PLIN2) by 31-97%, and fatty acid oxidation (PPARα, PGC1α, CPT1, UCP1) by 65-86, and reduced the percent fibrosis area by 92.7% relative to vehicle (and resultantly similar to normal diet mice) (all above: P<0.05) and by amounts greater than B or C alone or additively. This study demonstrates the positive interactive effects of bromocriptine and curcumin on advanced liver fibrosis in an MCD diet model of NASH. Disclosure T. Tsai: Employee; Self; VeroScience LLC. A. Cincotta: Employee; Self; VeroScience LLC.
Author CINCOTTA, ANTHONY
TSAI, TSUNG-HUANG
Author_xml – sequence: 1
  givenname: TSUNG-HUANG
  surname: TSAI
  fullname: TSAI, TSUNG-HUANG
  organization: Tiverton, RI
– sequence: 2
  givenname: ANTHONY
  surname: CINCOTTA
  fullname: CINCOTTA, ANTHONY
  organization: Tiverton, RI
BookMark eNotkU1r3DAQhkVJoZuPU__AQC-7FDeSZUtWbxtv0wSyaUhy6M3I8phV8EquJBf6r_oTa7NlDnN5eHhn3nNy5rxDQj4y-iXnXF53LVMZq0qWPb0jK6a4ynguf56RFaUsz5hU8gM5j_GNUirmWZG_J_or3AR_9CbYMVmHsL7ZwDhMEeopmOloHazrDdy7hEGbBMnDM3aTQdh2v7Uz2MGtbYOPNsLMatj7KSLsMR2sd7Mwqw9-WMQ77K2x6BKs9_VuAzuLaaY7HMD38OidHoxfWAMvCXXyBxx1smkWrx-3L3ebS_K-10PEq__7grzefnut77KHH9_v6-1DZkTBMsz7oitNzitTiZJVHPu8bFVfIW-5LEqhK1RSVEaZVupCUC6FlkK0qJXmqPgF-XTSjsH_mjCm5s1PYU4XmzwvKq5kQdlMfT5RZr49BuybMdijDn8aRpulkWZppFl-3Dzxfw19fsk
ContentType Journal Article
Copyright Copyright American Diabetes Association Jun 1, 2019
Copyright_xml – notice: Copyright American Diabetes Association Jun 1, 2019
DBID AAYXX
CITATION
K9.
NAPCQ
DOI 10.2337/db19-1851-P
DatabaseName CrossRef
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
DatabaseTitle CrossRef
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
DatabaseTitleList ProQuest Health & Medical Complete (Alumni)
CrossRef
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1939-327X
ExternalDocumentID 10_2337_db19_1851_P
Genre Conference Proceeding
GroupedDBID ---
.55
.XZ
08P
0R~
18M
29F
2WC
354
4.4
53G
5GY
5RE
5RS
5VS
6PF
8R4
8R5
AAQQT
AAWTL
AAYEP
AAYOK
AAYXX
ABOCM
ACGFO
ACGOD
ACPRK
ADBBV
AEGXH
AENEX
AERZD
AFHIN
AHMBA
AIAGR
AIZAD
ALIPV
ALMA_UNASSIGNED_HOLDINGS
BAWUL
BES
BTFSW
CITATION
CS3
DIK
DU5
E3Z
EBS
EDB
EJD
EMOBN
EX3
F5P
FRP
GX1
H13
HZ~
IAO
IEA
IHR
INH
INR
IOF
IPO
K2M
KQ8
L7B
M5~
O5R
O5S
O9-
OHH
OK1
OVD
P2P
PCD
Q2X
RHF
RHI
RPM
SJN
SV3
TDI
TEORI
TR2
VVN
W8F
WH7
WOQ
WOW
X7M
YFH
YHG
YOC
ZY1
~KM
K9.
NAPCQ
ID FETCH-LOGICAL-c641-e2f4d5c238c865183ef25b9f8e3b37456a8e9768c9cb7a460376a766bea9a3e93
ISSN 0012-1797
IngestDate Thu Oct 10 19:08:00 EDT 2024
Fri Aug 23 03:43:23 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue Supplement_1
Language English
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c641-e2f4d5c238c865183ef25b9f8e3b37456a8e9768c9cb7a460376a766bea9a3e93
PQID 2248397401
PQPubID 34443
ParticipantIDs proquest_journals_2248397401
crossref_primary_10_2337_db19_1851_P
PublicationCentury 2000
PublicationDate 2019-06-01
20190601
PublicationDateYYYYMMDD 2019-06-01
PublicationDate_xml – month: 06
  year: 2019
  text: 2019-06-01
  day: 01
PublicationDecade 2010
PublicationPlace New York
PublicationPlace_xml – name: New York
PublicationTitle Diabetes (New York, N.Y.)
PublicationYear 2019
Publisher American Diabetes Association
Publisher_xml – name: American Diabetes Association
SSID ssj0006060
Score 2.3404045
Snippet NASH is characterized by severe hepatic fibrosis that potentiates cirrhosis and hepatocellular carcinoma. The MCD diet also potentiates severe liver fibrosis...
SourceID proquest
crossref
SourceType Aggregation Database
SubjectTerms Antioxidants
Bromocriptine
Choline
Cirrhosis
Curcumin
Diet
Dopamine D2 receptors
Fatty liver
Fibrosis
Gene expression
GRP78 protein
Hepatocellular carcinoma
Inflammation
Interleukin 1
Intestinal microflora
Lipogenesis
Lipolysis
Liver
Liver cirrhosis
Methionine
Microbiomes
Neurodegeneration
Nitric-oxide synthase
Nutrient deficiency
Oxidation
Steatosis
Tumor necrosis factor-α
Title 1851-P: Bromocriptine (B) plus Curcumin (C) Interact to Reduce Advanced Fibrosis in a Mouse Methionine-Choline Deficient (MCD) Diet Model of Nonalcoholic Steatohepatitis (NASH)
URI https://www.proquest.com/docview/2248397401
Volume 68
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF6FIiEuqLxEaUFz6CERMiR27Hi5OQ7FBdVUxJHCyVpvN0okiKvGvvCruPD_mNm1XSfkULhYkeVdy5nPM9-M58HYqUNGhVPcra-oqTbqQS6FY0m050rYyke9TNkWsRfNhp_m7rzT-d3KWiqL7K38ubeu5H-kiudQrlQl-w-SbTbFE_gb5YtHlDAe7yRjtIID65Kc-jFl1RkFYFjjmNz96-_l5k1Y3sjyx2qtv9fSWR0EpNJIpJ1fqXOrHstsMgHO0HvOqUcJXi_whS83-NqrYqmjtsoKl7mmpRNFjSeqbqUX4YS2naxUoUeraXYbE8PX03dXklLJ0LdfKsreLlY6zhsH06iOQlTceNIKA-8OCGoFLJJpcK5RNp3FH61oFsTNeLDQhCgCrfDiJPoSf2tHNaiQqs6-qjX1wKbWqcYYK6OcucMtxx7N29rb81so1ZNQdVg1HeyzD7ajOwxcZXhDI6JbM1h_-t-xjk3OInpLtDylxSktTi_vsfs26jedHXD-uSEA6BOayqfqEUxZKC1-17rzNhHa5gGa3CSH7FHllUBgIPaYddT6CXtwUeVdPGW_zGbvYQtn0B33gDAGNcagG_agxhcUORh8QY0vqPEFeK0AjS_4G1_Q4Au6iK4eELZAYwvyBbSxBTvYgi4hq_eMJWcfkjCyqlkflvSGA0vZi-GVK5E_St9z0cyohe1mfOErJ3NGSPKFr5A4-5LLbCSGXh_tohh5XqYEF47iznN2sM7X6gUD7gmqr1Z9wV1ytjPHy2yOTF-iZ-C62RE7rf_39Np0dEn3yPaIndQySatXfpMi30WHgoZYvrzbLsfs4S26T9hBcVOqV8hii-y1xswfj8SUXA
link.rule.ids 315,783,787,27936,27937
linkProvider Flying Publisher
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=1851-P%3A+Bromocriptine+%28B%29+plus+Curcumin+%28C%29+Interact+to+Reduce+Advanced+Fibrosis+in+a+Mouse+Methionine-Choline+Deficient+%28MCD%29+Diet+Model+of+Nonalcoholic+Steatohepatitis+%28NASH%29&rft.jtitle=Diabetes+%28New+York%2C+N.Y.%29&rft.au=TSAI%2C+TSUNG-HUANG&rft.au=CINCOTTA%2C+ANTHONY&rft.date=2019-06-01&rft.issn=0012-1797&rft.eissn=1939-327X&rft.volume=68&rft.issue=Supplement_1&rft_id=info:doi/10.2337%2Fdb19-1851-P&rft.externalDBID=n%2Fa&rft.externalDocID=10_2337_db19_1851_P
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0012-1797&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0012-1797&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0012-1797&client=summon